118 related articles for article (PubMed ID: 11834971)
1. Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen.
Liuzzi G; Chirianni A; Clementi M; Zaccarelli M; Antinori A; Piazza M
AIDS; 2002 Feb; 16(3):503-4. PubMed ID: 11834971
[No Abstract] [Full Text] [Related]
2. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.
Servais J; Peytavin G; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
AIDS; 2001 May; 15(7):941-3. PubMed ID: 11399971
[No Abstract] [Full Text] [Related]
3. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
[TBL] [Abstract][Full Text] [Related]
4. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.
Kahlert C; Hupfer M; Wagels T; Bueche D; Fierz W; Walker UA; Vernazza PL
AIDS; 2004 Apr; 18(6):955-7. PubMed ID: 15060447
[No Abstract] [Full Text] [Related]
6. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.
Marra CM; Lockhart D; Zunt JR; Perrin M; Coombs RW; Collier AC
Neurology; 2003 Apr; 60(8):1388-90. PubMed ID: 12707454
[TBL] [Abstract][Full Text] [Related]
7. Differences in durability of treatment with initial PI-based regimens.
Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
[TBL] [Abstract][Full Text] [Related]
8. Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
Canestri A; Cisse M; Marcelin AG; Peytavin G; Traore E; Assoumou L; Traore O; Koita V; Diallo F; Sangare AT; Sidibé MK; Calvez V; Sylla A; Katlama C; Tubiana R
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):477-9. PubMed ID: 17622837
[No Abstract] [Full Text] [Related]
9. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
[TBL] [Abstract][Full Text] [Related]
11. Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment.
Ann Intern Med; 2002 Oct; 137(8):I48. PubMed ID: 12379092
[No Abstract] [Full Text] [Related]
12. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
[TBL] [Abstract][Full Text] [Related]
13. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
16. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
17. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
[No Abstract] [Full Text] [Related]
18. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
19. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.
Bernard L; Vuagnat A; Peytavin G; Hallouin MC; Bouhour D; Nguyen TH; Vildé JL; Bricaire F; Raguin G; de Truchis P; Ghez D; Duong M; Perronne C
Ann Intern Med; 2002 Oct; 137(8):656-9. PubMed ID: 12379065
[TBL] [Abstract][Full Text] [Related]
20. Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy.
Ball JK; Rowe T; Curran R; Irving WL; Beards GM; Sontag G; Youle M; Moyle G; Pillay D
Sex Transm Infect; 1999 Oct; 75(5):337-9. PubMed ID: 10616359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
